These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15817084)

  • 21. Elimination of late potentials by quinidine in a patient with Brugada syndrome.
    Watanabe H; Chinushi M; Osaki A; Okamura K; Izumi D; Komura S; Hosaka Y; Tanabe Y; Furushima H; Washizuka T; Aizawa Y
    J Electrocardiol; 2006 Jan; 39(1):63-6. PubMed ID: 16387054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrical storm in Brugada syndrome successfully treated using isoprenaline.
    Maury P; Couderc P; Delay M; Boveda S; Brugada J
    Europace; 2004 Mar; 6(2):130-3. PubMed ID: 15018871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brugada syndrome also linked to sudden cardiac death.
    Hari P; Chemiti GK; Joshi A
    Postgrad Med; 2001 Feb; 109(2):18. PubMed ID: 11272691
    [No Abstract]   [Full Text] [Related]  

  • 24. Near fatal electrical storm in a patient equipped with an implantable cardioverter defibrillator for Brugada syndrome.
    Chalvidan T; Deharo JC; Dieuzaide P; Defaye P; Djiane P
    Pacing Clin Electrophysiol; 2000 Mar; 23(3):410-2. PubMed ID: 10750147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts.
    Brugada P; Brugada R; Brugada J; Geelen P
    Am J Cardiol; 1999 Mar; 83(5B):98D-100D. PubMed ID: 10089849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chapter 1. Summary of the CCS Consensus Conference on prevention of sudden death from cardiac arrhythmia.
    Connolly SJ; Talajic M
    Can J Cardiol; 2000 Oct; 16(10):1298-302. PubMed ID: 11064304
    [No Abstract]   [Full Text] [Related]  

  • 28. Brugada syndrome and vasospasitc angina do coexist: potential clinical importance.
    Aizawa Y; Sato A
    Intern Med; 2006; 45(2):43-4. PubMed ID: 16484737
    [No Abstract]   [Full Text] [Related]  

  • 29. Application of the main implantable cardioverter-defibrillator trials and the 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
    Proclemer A; Ghidina M
    J Cardiovasc Med (Hagerstown); 2007 May; 8(5):320-3. PubMed ID: 17443096
    [No Abstract]   [Full Text] [Related]  

  • 30. Brugada syndrome: an electrocardiographic diagnosis not to be missed.
    Brugada P
    Heart; 2000 Jul; 84(1):1-2. PubMed ID: 10862570
    [No Abstract]   [Full Text] [Related]  

  • 31. [Problems of management for workers with Brugada syndrome].
    Enta K; Nagatomo T; Murakami T; Sashihara S
    Sangyo Eiseigaku Zasshi; 2004 Jan; 46(1):10-2. PubMed ID: 15024838
    [No Abstract]   [Full Text] [Related]  

  • 32. Possible role of epicardial left ventricular programmed stimulation in Brugada syndrome.
    Carlsson J; Erdogan A; Schulte B; Neuzner J; Pitschner HF
    Pacing Clin Electrophysiol; 2001 Feb; 24(2):247-9. PubMed ID: 11270709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defibrillation threshold testing in implantable cardioverter-defibrillators: might less be more than enough?
    Curtis AB
    J Am Coll Cardiol; 2008 Aug; 52(7):557-8. PubMed ID: 18687250
    [No Abstract]   [Full Text] [Related]  

  • 34. [Regarding the French Society of Cardiologists' guidelines on the indications for implantable automatic ventricular defibrillators].
    Daubert JC
    Arch Mal Coeur Vaiss; 2006 Feb; 99(2):93-4. PubMed ID: 16555690
    [No Abstract]   [Full Text] [Related]  

  • 35. Chapter 2. Guidelines and recommendations for ICD therapy.
    Noorani HZ
    Can J Cardiol; 2000 Oct; 16(10):1303-6. PubMed ID: 11064305
    [No Abstract]   [Full Text] [Related]  

  • 36. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators.
    Buxton AE; Sweeney MO; Wathen MS; Josephson ME; Otterness MF; Hogan-Miller E; Stark AJ; Degroot PJ;
    J Am Coll Cardiol; 2005 Jul; 46(2):310-6. PubMed ID: 16022960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiological impact of microvolt T-wave alternans in sudden cardiac death primary prevention.
    Daccarett M; Serafimovski N; Machado C
    Int J Cardiol; 2007 Jun; 119(1):127-8; author reply 129-30. PubMed ID: 17049385
    [No Abstract]   [Full Text] [Related]  

  • 38. Implantable cardioverter defibrillators.
    Med Lett Drugs Ther; 2009 Jan; 51(1304):6-7. PubMed ID: 19172139
    [No Abstract]   [Full Text] [Related]  

  • 39. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope.
    Márquez MF; Rivera J; Hermosillo AG; Iturralde P; Colín L; Moragrega JL; Cárdenas M
    Pacing Clin Electrophysiol; 2005 Aug; 28(8):870-3. PubMed ID: 16105018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of high defibrillation threshold.
    Uyguanco ER; Berger A; Budzikowski AS; Gunsburg M; Kassotis J
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1237-48. PubMed ID: 18939911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.